Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosisopen access
- Authors
- Cho, In-Jin; Chung, Ho-Yeon; Kim, Sung-Woon; Lee, Jae-Won; Lee, Tae-Won; Kim, Hye-Soon; Kim, Sin-Gon; Choi, Han Seok; Choi, Sung-Hee; Shin, Chan Soo; Oh, Ki-Won; Min, Yong-Ki; Koh, Jung-Min; Rhee, Yumie; Byun, Dong-Won; Chung, Yoon-Sok; Park, Jeong Hyun; Chung, Dong Jin; Shong, Minho; Hong, Eun-Gyoung; Lee, Chang Beom; Baek, Ki Hyun; Kang, Moo-Il
- Issue Date
- Sep-2015
- Publisher
- KOREAN ENDOCRINE SOC
- Keywords
- Ibandronate; Cholecalciferol; 25-hydroxyvitamin D; Bone markers
- Citation
- ENDOCRINOLOGY AND METABOLISM, v.30, no.3, pp.272 - 279
- Indexed
- SCOPUS
KCI
- Journal Title
- ENDOCRINOLOGY AND METABOLISM
- Volume
- 30
- Number
- 3
- Start Page
- 272
- End Page
- 279
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156458
- DOI
- 10.3803/EnM.2015.30.3.272
- ISSN
- 2093-596X
- Abstract
- Background: The present study evaluated the efficacy of a combination of ibandronate and cholecalciferol on the restoration of the levels of 25-hydroxyvitamin D (25[OH] D) and various bone markers in postmenopausal women with osteoporosis. Methods: This was a randomized, double-blind, active-controlled, prospective 16-week clinical trial conducted in 20 different hospitals. A total of 201 postmenopausal women with osteoporosis were assigned randomly to one of two groups: the IBN group, which received a once-monthly pill containing 150 mg ibandronate (n=99), or the IBN+ group, which received a once-monthly pill containing 150 mg ibandronate and 24,000 IU cholecalciferol (n=102). Serum levels of 25(OH) D, parathyroid hormone (PTH), and various bone markers were assessed at baseline and at the end of a 16-week treatment period. Results: After 16 weeks of treatment, the mean serum levels of 25(OH) D significantly increased from 21.0 to 25.3 ng/mL in the IBN+ group but significantly decreased from 20.6 to 17.4 ng/mL in the IBN group. Additionally, both groups exhibited significant increases in mean serum levels of PTH but significant decreases in serum levels of bone-specific alkaline phosphatase and C-telopeptide of type 1 collagen (CTX) at 16 weeks; no significant differences were observed between the groups. However, in subjects with a vitamin D deficiency, IBN+ treatment resulted in a significant decrease in serum CTX levels compared with IBN treatment. Conclusion: The present findings demonstrate that a once-monthly pill containing ibandronate and cholecalciferol may be useful for the amelioration of vitamin D deficiency in patients with postmenopausal osteoporosis. Moreover, this treatment combination effectively decreased serum levels of resorption markers, especially in subjects with a vitamin D deficiency, over the 16-week treatment period.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 내과학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/156458)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.